Epigenetics\'s Function in Cardiovascular and Periodontal Diseases

Maglio Urganci^*
*Correspondence: Maglio Urganci, Department of Medicine, University Medical & Dental College, Faisalabad 38000, Pakistan, Email:

Keywords

Epigenetics • Cardiovascular diseases • Periodontal diseases • DNA methylation

Introduction

Epigenetics, a burgeoning field at the intersection of genetics and environmental influences, has revolutionized our understanding of disease mechanisms beyond genetic mutations. It encompasses heritable changes in gene expression that occur without altering the underlying DNA sequence, playing a pivotal role in various physiological processes and disease pathogenesis. Among the multifaceted conditions influenced by epigenetic factors, Cardiovascular Diseases (CVD) and Periodontal Diseases (PD) stand out due to their widespread prevalence and significant impact on public health [1].

Cardiovascular diseases, including coronary artery disease, hypertension and stroke, are complex disorders influenced by genetic predisposition, lifestyle factors and chronic inflammation. Epigenetic modifications such as DNA methylation, histone modifications and microRNAs have been implicated in regulating key pathways involved in cardiovascular health. For instance, aberrant DNA methylation patterns in promoter regions of genes associated with lipid metabolism and inflammation can predispose individuals to atherosclerosis and hypertension. Histone modifications dynamically regulate chromatin structure, influencing gene accessibility and transcriptional activity of critical genes in cardiac function and vascular integrity. Moreover, non-coding RNAs, such as microRNAs and long non-coding RNAs, play essential roles in post-transcriptional gene regulation, affecting processes like endothelial dysfunction and vascular remodeling in response to cardiovascular stressors [2].

Literature Review

Periodontal diseases, characterized by chronic inflammation and destruction of tooth-supporting tissues, are intricately linked to oral microbiota dysbiosis and host immune responses. Epigenetic mechanisms contribute significantly to the regulation of inflammatory pathways and tissue remodeling processes in periodontitis. DNA methylation profiles in gingival tissues and periodontal ligament cells have been associated with disease severity and response to treatment. Histone modifications modulate the expression of genes involved in immune responses and bone metabolism, influencing the balance between periodontal tissue destruction and repair. Additionally, microRNAs regulate the expression of cytokines and matrix metalloproteinases, contributing to the chronic inflammatory state observed in periodontitis [3].

Understanding the epigenetic underpinnings of cardiovascular and periodontal diseases opens avenues for novel therapeutic strategies. Targeting specific epigenetic modifications could potentially mitigate disease progression and improve treatment outcomes. For instance, inhibitors of DNA methyltransferases or histone deacetylases show promise in preclinical studies for their anti-inflammatory and cardioprotective effects. Similarly, manipulating microRNA expression holds therapeutic potential in modulating immune responses and tissue regeneration in periodontitis. However, translating these findings into clinical practice requires further elucidation of the complex interactions between epigenetic alterations, environmental factors and disease phenotypes. Epigenetics represents a fundamental mechanism underlying the pathogenesis of cardiovascular and periodontal diseases. By influencing gene expression patterns without altering DNA sequences, epigenetic modifications contribute to disease susceptibility, progression and treatment response. Continued research into epigenetic mechanisms promises to uncover new biomarkers and therapeutic targets, paving the way for personalized medicine approaches in managing these prevalent chronic conditions [4].

Discussion

Several key challenges and opportunities emerge in the field of epigenetics as it relates to cardiovascular and periodontal diseases. One significant challenge is deciphering the complex interactions between genetic predisposition, environmental exposures and epigenetic modifications in disease pathogenesis. Epigenome-Wide Association Studies (EWAS) and integrative omics approaches hold promise in unraveling these interactions, providing a comprehensive understanding of disease mechanisms. The development of robust biomarkers remains critical for early diagnosis, prognosis and monitoring of disease progression. Epigenetic signatures, including DNA methylation patterns and non-coding RNA profiles, offer potential biomarkers that could improve clinical decision-making and patient stratification. However, validating these biomarkers across diverse populations and disease stages is essential to ensure their reliability and clinical utility [5].

Translating epigenetic discoveries into effective interventions poses both opportunities and challenges. Epigenetic drugs targeting DNA methyltransferases, histone modifiers and microRNAs are currently under investigation for their potential in modifying disease outcomes. Clinical trials evaluating the efficacy, safety and long-term effects of these therapies are necessary to establish their clinical relevance and utility in managing cardiovascular and periodontal diseases. Addressing ethical considerations and societal implications of epigenetic research and therapies is crucial. Issues such as data privacy, informed consent and equitable access to emerging treatments must be carefully navigated to ensure responsible and ethical implementation of epigenetic-based approaches in healthcare [6].

Conclusion

Epigenetics continues to reshape our understanding of cardiovascular and periodontal diseases by elucidating the intricate mechanisms underlying disease susceptibility, progression and treatment response. By exploring the dynamic interplay between genetic and environmental factors through epigenetic modifications, researchers aim to uncover novel insights into disease pathogenesis and identify innovative therapeutic strategies. The interplay between cardiovascular and periodontal diseases highlights the interconnectedness of systemic and oral health. Shared risk factors such as inflammation, oxidative stress and dyslipidemia contribute to the development and progression of both conditions, underscoring the importance of integrated approaches to disease prevention and management.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Lamont, Richard J., Hyun Koo and George Hajishengallis. "The oral microbiota: Dynamic communities and host interactions." Nat Rev Microbiol 16 (2018): 745-759.

Google Scholar, Crossref, Indexed at

2. Konkel, Joanne E., Conor O'Boyle and Siddharth Krishnan. "Distal consequences of oral inflammation." Front immunol 10 (2019): 1403.

Google Scholar, Crossref, Indexed at

3. Makkar, Hina, Mark A. Reynolds, Abhishek Wadhawan and Aline Dagdag, et al. "Periodontal, metabolic and cardiovascular disease: Exploring the role of inflammation and mental health." Pteridines 29 (2018): 124-163.

Google Scholar, Crossref, Indexed at

4. Teles, Ricardo and C‐Y. Wang. "Mechanisms involved in the association between peridontal diseases and cardiovascular disease." Oral Dis 17 (2011): 450-461.

Google Scholar, Crossref, Indexed at

5. Ahmad, Paras, Anas Imran Arshad, Elena Della Bella and Zohaib Khurshid, et al. "Systemic manifestations of the periodontal disease: A bibliometric review." Molecules 25 (2020): 4508.

Google Scholar, Crossref, Indexed at

6. Bibi, Tauqeer, Zohaib Khurshid, Ambreen Rehman and Eisha Imran, et al. "Gingival Crevicular Fluid (GCF): A diagnostic tool for the detection of periodontal health and diseases." Molecules 26 (2021): 1208.

Google Scholar, Crossref, Indexed at